Ruxolitinib is the first topical JAK inhibitor approved in the US for pediatric AD.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ruxolitinib-cream-approved-children-aged-2-11-atopic-2025a1000ow3?src=rss
Author :
Publish date : 2025-09-19 05:22:00
Copyright for syndicated content belongs to the linked Source.